WO2007037795A3 - Stable aqueous protein or antibody pharmaceutical formulations and their preparation - Google Patents

Stable aqueous protein or antibody pharmaceutical formulations and their preparation Download PDF

Info

Publication number
WO2007037795A3
WO2007037795A3 PCT/US2006/030610 US2006030610W WO2007037795A3 WO 2007037795 A3 WO2007037795 A3 WO 2007037795A3 US 2006030610 W US2006030610 W US 2006030610W WO 2007037795 A3 WO2007037795 A3 WO 2007037795A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulations
preparation
aqueous protein
stable aqueous
antibody pharmaceutical
Prior art date
Application number
PCT/US2006/030610
Other languages
French (fr)
Other versions
WO2007037795A2 (en
Inventor
Tiansheng Li
Christopher James Sloey
Original Assignee
Amgen Inc
Tiansheng Li
Christopher James Sloey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Tiansheng Li, Christopher James Sloey filed Critical Amgen Inc
Priority to AU2006295340A priority Critical patent/AU2006295340B2/en
Priority to EP06800835.8A priority patent/EP1916997B1/en
Priority to CA2618068A priority patent/CA2618068C/en
Publication of WO2007037795A2 publication Critical patent/WO2007037795A2/en
Publication of WO2007037795A3 publication Critical patent/WO2007037795A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
PCT/US2006/030610 2005-08-05 2006-08-04 Stable aqueous protein or antibody pharmaceutical formulations and their preparation WO2007037795A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2006295340A AU2006295340B2 (en) 2005-08-05 2006-08-04 Stable aqueous protein or antibody pharmaceutical formulations and their preparation
EP06800835.8A EP1916997B1 (en) 2005-08-05 2006-08-04 Stable aqueous protein pharmaceutical formulations and their preparation
CA2618068A CA2618068C (en) 2005-08-05 2006-08-04 Stable aqueous protein or antibody pharmaceutical formulations and their preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70589405P 2005-08-05 2005-08-05
US60/705,894 2005-08-05

Publications (2)

Publication Number Publication Date
WO2007037795A2 WO2007037795A2 (en) 2007-04-05
WO2007037795A3 true WO2007037795A3 (en) 2007-12-13

Family

ID=37835202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/030610 WO2007037795A2 (en) 2005-08-05 2006-08-04 Stable aqueous protein or antibody pharmaceutical formulations and their preparation

Country Status (5)

Country Link
US (5) US7790679B2 (en)
EP (1) EP1916997B1 (en)
AU (1) AU2006295340B2 (en)
CA (2) CA2915270C (en)
WO (1) WO2007037795A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
US9309316B2 (en) * 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058567A1 (en) * 2005-12-20 2008-02-13 Bristol Myers Squibb Co FORMULATIONS OF STABLE PROTEINS
WO2007108505A1 (en) * 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha Erythropoietin solution preparation
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5362715B2 (en) * 2007-06-29 2013-12-11 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー Liquid protein formulation containing GDF-5 for use at high temperatures
EP2187932B1 (en) * 2007-08-07 2015-01-28 DePuy Synthes Products, LLC Protein formulations comprising gdf-5 in aqueous acidic solution
EP3381445B1 (en) * 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2720845A1 (en) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
RU2011126338A (en) * 2008-11-28 2013-01-10 Эбботт Лэборетриз STABLE COMPOSITIONS OF ANTIBODIES AND METHODS FOR THEIR STABILIZATION
JP2012526121A (en) * 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド Stable high protein concentration formulation of human anti-TNF alpha antibody
US8859235B2 (en) 2009-08-14 2014-10-14 Basf Se Methods in cell cultures, and related inventions, employing certain additives
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
WO2011088120A1 (en) 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
JP5859987B2 (en) 2010-02-24 2016-02-16 アレコー リミテッド Protein preparation
KR20120130757A (en) 2010-02-26 2012-12-03 노보 노르디스크 에이/에스 Stable antibody containing compositions
CA2976671C (en) 2010-03-01 2021-01-12 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US20130171128A1 (en) * 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
CA2800188A1 (en) * 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
TWI606840B (en) 2010-11-11 2017-12-01 艾伯維生物技術有限責任公司 Improved high concentration anti-tnfα antibody liquid formulations
WO2012106634A1 (en) * 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
US10064951B2 (en) * 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
IN2015KN00657A (en) 2012-09-20 2015-07-17 Morphosys Ag
GB2516808A (en) * 2013-05-31 2015-02-11 Innova Biosciences Ltd Antibody composition and buffer system therefor
US10987425B2 (en) * 2013-09-27 2021-04-27 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting human growth hormone immunoglobulin conjugate
GB201703063D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3624846A1 (en) 2017-05-16 2020-03-25 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
MA55033A (en) 2019-02-18 2021-12-29 Lilly Co Eli THERAPEUTIC ANTIBODY FORMULATION
JP2022536646A (en) * 2019-06-11 2022-08-18 マクロジェニクス，インコーポレーテッド Pharmaceutical formulations of bispecific diabodies and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0280358B1 (en) * 1987-02-20 1992-12-30 Akzo N.V. Stabilized aqueous composition containing antibodies
US5503827A (en) * 1991-08-15 1996-04-02 Boehringer Mannheim Gmbh Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5762923A (en) * 1995-04-06 1998-06-09 Hoffmann-La Roche Inc. Stabilized interferon alpha solutions
WO2000061169A1 (en) * 1999-04-09 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical compositions of erythropoietin
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO2003020299A1 (en) * 2001-08-30 2003-03-13 Kirin-Amgen, Inc. L-methionine as a stabilizer for nesp/epo in hsa-free formulations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2296994A1 (en) * 1975-01-10 1976-08-06 Nodet Gougis MEASURING DISPENSER WITH SEALING DEVICE
US4558033A (en) 1983-06-06 1985-12-10 Amgen Potentiation of the effects of insulin by peptides
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
DE69033584T2 (en) 1989-10-16 2001-03-08 Amgen Inc., Thousand Oaks Stem cell factor
JPH04218000A (en) 1990-02-13 1992-08-07 Kirin Amgen Inc Modified polypeptide
CA2107553C (en) 1991-04-05 2001-07-31 Nancy Lin Monoclonal antibodies to stem cell factor receptors
US5407810A (en) * 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5696250A (en) 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
US5989538A (en) 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
WO1996040912A1 (en) * 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
US6964947B1 (en) * 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
CN1981868A (en) 2000-03-31 2007-06-20 拜奥根Idec公司 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
PT1311285E (en) * 2000-05-15 2005-06-30 Hoffmann La Roche Liquid pharmaceutical composition containing a derivative of erythropoietin
JP2002082772A (en) * 2000-06-28 2002-03-22 Hitachi Ltd Touch panel, its manufacturing method and screen input type display device using the same touch panel
ATE390436T1 (en) * 2000-10-31 2008-04-15 Barofold Inc IMPROVED DECAY AND REFOLDING OF PROTEINS USING HIGH PRESSURE
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
MXPA04008215A (en) * 2002-02-27 2004-11-26 Immunex Corp Polypeptide formulation.
WO2003099284A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7146992B2 (en) * 2002-07-02 2006-12-12 Maytag Corporation Dishwasher pump and filtration system
CA2497007A1 (en) 2002-09-09 2004-03-18 Amgen Inc. 1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivatives s tnf-alpha and interleukin lowering agents for the treatment of inflammations
US7141544B2 (en) 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
US20050267027A1 (en) * 2004-04-05 2005-12-01 Lounsbury Karen M Use of erythropoietin for treatment of cancer
WO2006028956A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
US7323909B2 (en) * 2005-07-29 2008-01-29 Sequence Design, Inc. Automatic extension of clock gating technique to fine-grained power gating
US7790679B2 (en) * 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0280358B1 (en) * 1987-02-20 1992-12-30 Akzo N.V. Stabilized aqueous composition containing antibodies
US5503827A (en) * 1991-08-15 1996-04-02 Boehringer Mannheim Gmbh Process for the production of multi-dose pharmaceutical preparations containing isolated or recombinantly produced human protein for infusion or injection purposes
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5762923A (en) * 1995-04-06 1998-06-09 Hoffmann-La Roche Inc. Stabilized interferon alpha solutions
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO2000061169A1 (en) * 1999-04-09 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Pharmaceutical compositions of erythropoietin
WO2003020299A1 (en) * 2001-08-30 2003-03-13 Kirin-Amgen, Inc. L-methionine as a stabilizer for nesp/epo in hsa-free formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THIRUMANGALATHU RENUKA ET AL: "Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 95, no. 7, July 2006 (2006-07-01), pages 1480 - 1497, XP002453901, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
EP1916997A2 (en) 2008-05-07
EP1916997B1 (en) 2018-04-18
US10668154B2 (en) 2020-06-02
US7790679B2 (en) 2010-09-07
AU2006295340A1 (en) 2007-04-05
US8314063B2 (en) 2012-11-20
WO2007037795A2 (en) 2007-04-05
CA2915270A1 (en) 2007-04-05
US20070053871A1 (en) 2007-03-08
US20130071387A1 (en) 2013-03-21
CA2915270C (en) 2017-07-11
US8980256B2 (en) 2015-03-17
US20150335748A1 (en) 2015-11-26
US20210069334A1 (en) 2021-03-11
CA2618068A1 (en) 2007-04-05
AU2006295340A2 (en) 2008-04-24
CA2618068C (en) 2016-02-16
AU2006295340B2 (en) 2010-11-11
US20100316593A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
WO2007037795A3 (en) Stable aqueous protein or antibody pharmaceutical formulations and their preparation
MY142354A (en) Acidic insulin preparations having improved stability
WO2009043049A3 (en) Pharmaceutical formulations
WO2010129469A8 (en) Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2004071439A3 (en) Immunoglobulin formulation and method of preparation thereof
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
RS52706B (en) Dried reconstituted vesicle formation for pharmaceutical application
EP1483277A4 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2006020935A3 (en) Stabilizing formulations
DK1372608T3 (en) Medical aerosol formulations
EA200800360A1 (en) FORMS WITH HIGH CONTENT OF DRUGS AND DOSED FORMS
AU2003215245A1 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
CY1107819T1 (en) PHARMACEUTICAL FORM OF OLANZAPIN
ATE531274T1 (en) POWDER COMPOSITIONS OF FAT-SOLUBLE SUBSTANCES
WO2005107723A3 (en) Transdermal delivery systems and transdermal chelation preparations
PL1767090T3 (en) Clathrate compound, method of controlling concentration of aqueous solution of agricultural-chemical active ingredient, and agricultural-chemical preparation
WO2004086882A8 (en) Powderous formulations of fat-soluble active ingredients
TW200727921A (en) Formulation for prolonged release of active ingredients of medicaments
DE60034149D1 (en) HYDROPHOBIC AMINO ACIDS CONTAINING A DRY COMPOSITION
ATE262898T1 (en) CONTROLLED RELEASE FORMULATION CONTAINING BUPROPION-HCI AS THE ACTIVE INGREDIENT
WO2005123137A3 (en) Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride
ATE424399T1 (en) PHARMACEUTICAL COMPOSITIONS OF RISPERIDONE IN AQUEOUS SOLUTION
IL163552A0 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2618068

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006295340

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006800835

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006295340

Country of ref document: AU

Date of ref document: 20060804

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06800835

Country of ref document: EP

Kind code of ref document: A2